Secretory clusterin inhibits osteoclastogenesis by attenuating M-CSF-dependent osteoclast precursor cell proliferation

Bongkun Choi, Soon Suk Kang, Sang Wook Kang, Bon Hong Min, Eun Jin Lee, Da Hyun Song, Sang Min Kim, Youngsup Song, Seung Yong Yoon, Eun Ju Chang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Secretory clusterin (sCLU)/apolipoprotein J is a multifunctional glycoprotein that is ubiquitously expressed in various tissues. Reduced sCLU in the joints of patients with bone erosive disease is associated with disease activity; however, its exact role has yet to be elucidated. Here, we report that CLU is expressed and secreted during osteoclastogenesis in mouse bone marrow-derived macrophages (BMMs) that are treated with receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). CLU-deficient BMMs obtained from CLU-/- mice exhibited no significant alterations in OC differentiation in comparison with BMMs obtained from wild-type mice. In contrast, exogenous sCLU treatment significantly inhibited OC formation in both BMMs and OC precursor cultures. The inhibitory effect of sCLU was more prominent in BMMs than OC precursor cultures. Interestingly, treating BMMs with sCLU decreased the proliferative effects elicited by M-CSF and suppressed M-CSF-induced ERK activation of OC precursor cells without causing apoptotic cell death. This study provides the first evidence that sCLU reduces OC formation by inhibiting the actions of M-CSF, thereby suggesting its protective role in bone erosion.

Original languageEnglish
Pages (from-to)105-109
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume450
Issue number1
DOIs
Publication statusPublished - 2014 Jul 18

Fingerprint

Clusterin
Macrophage Colony-Stimulating Factor
Cell proliferation
Osteoclasts
Osteogenesis
Macrophages
Bone
Cell Proliferation
Cell culture
RANK Ligand
Bone Diseases
Cell death
Glycoproteins
Cell Death
Joints
Erosion
Chemical activation
Bone and Bones
Tissue

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Secretory clusterin inhibits osteoclastogenesis by attenuating M-CSF-dependent osteoclast precursor cell proliferation. / Choi, Bongkun; Kang, Soon Suk; Kang, Sang Wook; Min, Bon Hong; Lee, Eun Jin; Song, Da Hyun; Kim, Sang Min; Song, Youngsup; Yoon, Seung Yong; Chang, Eun Ju.

In: Biochemical and Biophysical Research Communications, Vol. 450, No. 1, 18.07.2014, p. 105-109.

Research output: Contribution to journalArticle

Choi, Bongkun ; Kang, Soon Suk ; Kang, Sang Wook ; Min, Bon Hong ; Lee, Eun Jin ; Song, Da Hyun ; Kim, Sang Min ; Song, Youngsup ; Yoon, Seung Yong ; Chang, Eun Ju. / Secretory clusterin inhibits osteoclastogenesis by attenuating M-CSF-dependent osteoclast precursor cell proliferation. In: Biochemical and Biophysical Research Communications. 2014 ; Vol. 450, No. 1. pp. 105-109.
@article{f052f3c30f1845bc865f6a268871000b,
title = "Secretory clusterin inhibits osteoclastogenesis by attenuating M-CSF-dependent osteoclast precursor cell proliferation",
abstract = "Secretory clusterin (sCLU)/apolipoprotein J is a multifunctional glycoprotein that is ubiquitously expressed in various tissues. Reduced sCLU in the joints of patients with bone erosive disease is associated with disease activity; however, its exact role has yet to be elucidated. Here, we report that CLU is expressed and secreted during osteoclastogenesis in mouse bone marrow-derived macrophages (BMMs) that are treated with receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). CLU-deficient BMMs obtained from CLU-/- mice exhibited no significant alterations in OC differentiation in comparison with BMMs obtained from wild-type mice. In contrast, exogenous sCLU treatment significantly inhibited OC formation in both BMMs and OC precursor cultures. The inhibitory effect of sCLU was more prominent in BMMs than OC precursor cultures. Interestingly, treating BMMs with sCLU decreased the proliferative effects elicited by M-CSF and suppressed M-CSF-induced ERK activation of OC precursor cells without causing apoptotic cell death. This study provides the first evidence that sCLU reduces OC formation by inhibiting the actions of M-CSF, thereby suggesting its protective role in bone erosion.",
keywords = "Clusterin, Differentiation, ERK, Osteoclast, Proliferation",
author = "Bongkun Choi and Kang, {Soon Suk} and Kang, {Sang Wook} and Min, {Bon Hong} and Lee, {Eun Jin} and Song, {Da Hyun} and Kim, {Sang Min} and Youngsup Song and Yoon, {Seung Yong} and Chang, {Eun Ju}",
year = "2014",
month = "7",
day = "18",
doi = "10.1016/j.bbrc.2014.05.074",
language = "English",
volume = "450",
pages = "105--109",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Secretory clusterin inhibits osteoclastogenesis by attenuating M-CSF-dependent osteoclast precursor cell proliferation

AU - Choi, Bongkun

AU - Kang, Soon Suk

AU - Kang, Sang Wook

AU - Min, Bon Hong

AU - Lee, Eun Jin

AU - Song, Da Hyun

AU - Kim, Sang Min

AU - Song, Youngsup

AU - Yoon, Seung Yong

AU - Chang, Eun Ju

PY - 2014/7/18

Y1 - 2014/7/18

N2 - Secretory clusterin (sCLU)/apolipoprotein J is a multifunctional glycoprotein that is ubiquitously expressed in various tissues. Reduced sCLU in the joints of patients with bone erosive disease is associated with disease activity; however, its exact role has yet to be elucidated. Here, we report that CLU is expressed and secreted during osteoclastogenesis in mouse bone marrow-derived macrophages (BMMs) that are treated with receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). CLU-deficient BMMs obtained from CLU-/- mice exhibited no significant alterations in OC differentiation in comparison with BMMs obtained from wild-type mice. In contrast, exogenous sCLU treatment significantly inhibited OC formation in both BMMs and OC precursor cultures. The inhibitory effect of sCLU was more prominent in BMMs than OC precursor cultures. Interestingly, treating BMMs with sCLU decreased the proliferative effects elicited by M-CSF and suppressed M-CSF-induced ERK activation of OC precursor cells without causing apoptotic cell death. This study provides the first evidence that sCLU reduces OC formation by inhibiting the actions of M-CSF, thereby suggesting its protective role in bone erosion.

AB - Secretory clusterin (sCLU)/apolipoprotein J is a multifunctional glycoprotein that is ubiquitously expressed in various tissues. Reduced sCLU in the joints of patients with bone erosive disease is associated with disease activity; however, its exact role has yet to be elucidated. Here, we report that CLU is expressed and secreted during osteoclastogenesis in mouse bone marrow-derived macrophages (BMMs) that are treated with receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). CLU-deficient BMMs obtained from CLU-/- mice exhibited no significant alterations in OC differentiation in comparison with BMMs obtained from wild-type mice. In contrast, exogenous sCLU treatment significantly inhibited OC formation in both BMMs and OC precursor cultures. The inhibitory effect of sCLU was more prominent in BMMs than OC precursor cultures. Interestingly, treating BMMs with sCLU decreased the proliferative effects elicited by M-CSF and suppressed M-CSF-induced ERK activation of OC precursor cells without causing apoptotic cell death. This study provides the first evidence that sCLU reduces OC formation by inhibiting the actions of M-CSF, thereby suggesting its protective role in bone erosion.

KW - Clusterin

KW - Differentiation

KW - ERK

KW - Osteoclast

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=84904731168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904731168&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2014.05.074

DO - 10.1016/j.bbrc.2014.05.074

M3 - Article

VL - 450

SP - 105

EP - 109

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 1

ER -